Correlation between progression free survival and dynamic susceptibility contrast MRI perfusion in WHO grade III glioma subtypes

Journal of Neuro-Oncology

Volumn 116, Issue 2, 2014, Pages 325-331

  Mangla, Rajiv ^a   Ginat, Daniel Thomas ^b   Kamalian, Shervin ^c   Milano, Michael T ^a   Korones, David N ^a   Walter, Kevin A ^a   Ekholm, Sven ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Grade III astrocytoma; MR perfusion; Progression free survival

Indexed keywords

BEVACIZUMAB; CARMUSTINE; IRINOTECAN; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; ASTROCYTOMA; BLOOD VOLUME; BRAIN BLOOD FLOW; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE SCANNER; OLIGODENDROGLIOMA; PERFUSION WEIGHTED IMAGING; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; CHILD; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 84893687550     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1298-9     Document Type: Article

References (32)

1. Kleihues P, Cavenee WK (2000) Pathology and genetics of tumours of the nervous system. IARC, Lyon
2. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109
3. Aronen HJ, Gazit IE, Louis DN et al (1994) Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 191:41-51
4. Leon SP, Folkerth RD, Black P (1996) Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 77:362-372
5. Von Deimling A, Louis DN, von Ammon K et al (1992) Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 52:4277-4279
6. Curran WJ, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85:704-710
7. Scott SCB, Scarantino C, Urtasun R et al (1998) Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 40:51-55
8. Bruner JM, Inouye L, Fuller GN, Langford LA (1997) Diagnostic discrepancies and their clinical impact in a neuropathology referral practice. Cancer 79:796-803
9. Law M, Oh S, Babb JS et al (2006) Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging - prediction of patient clinical response. Radiology 238:658-667
10. Oh J, Henry RG, Pirzkall A et al (2004) Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 19:546-554
11. Pope WB, Sayre J, Perlina A et al (2005) MR imaging correlates of survival in patients with high-grade gliomas. Am J Neuroradiol 26:2466-2474
12. Li Y, Lupo JM, Polley MY et al (2011) Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme. Neuro Oncol 13:546-557
13. Haselhorst R, Kappos L, Bilecen D et al (2000) Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction. J Magn Reson Imaging 11:495-505
14. Wetzel SG, Cha S, Johnson G et al (2002) Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology 224:797-803
15. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
16. Law M, Young RJ, Babb JS et al (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247:490-498
17. Stark AM, Nabavi A, Mehdorn HM, Blomer U (2005) Glioblastoma multiforme: report of 267 cases treated at a single institution. Surg Neurol 63:162-169
18. Stupp R, Reni M, Gatta G, Mazza E, Vecht C (2007) Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol 63:72-80
19. Hirai T, Murakami R, Nakamura H et al (2008) Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol 29:1505-1510
20. Cha S, Tihan T, Crawford F et al (2005) Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. Am J Neuroradiol 26:266-273
21. Lev MH, Ozsunar Y, Henson JW et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendroglimoas. AJNR Am J Neuroradiol 25:214-221
22. Bisdas S, Kirkpatrick M, Giglio P et al (2009) Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? AJNR Am J Neuroradiol 30:681-688
23. Schiffer D, Dutto A, Cavalla P et al (1997) Prognostic factors in oligodendroglioma. Can J Neurol Sci 24:313-319
24. Mork SJ, Halvorsen TB, Lindegaard KF, Eide GE (1986) Oligodendroglioma: histologic evaluation and prognosis. J Neuropathol Exp Neurol 45:65-78
25. Engelhard HH, Stelea A, Mundt A (2003) Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. Surg Neurol 60:443-456
26. Whitmore RG et al (2007) Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 107:600-609
27. Christov C, Adle-Biassette H, Le Guerinel C et al (1998) Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol 24:29-35
28. Lafuente JV, Adán B, Alkiza K, Garibi JM, Rossi M, Cruz-Sánchez FF (1999) Expression of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-beta) in human gliomas. J Mol Neurosci 13:177-185
29. Pietsch T, Valter MM, Wolf HK et al (1997) Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93:109-117
30. Maia AC Jr, Malheiros SM, da Rocha AJ et al (2005) MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 26:777-783
31. Netto GC, Bleil CB, Hilbig A et al (2008) Immunohistochemical evaluation of the microvascular density through the expression of TGF-b (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas. Neuropathology 28:17-23
32. Boxerman J, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade whereas uncorrected maps do not. AJNR Am J Neuroradiol 27:859-867